⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Nicorandil
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-11-10 — Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging: [mechanism-plausible] A therapeutic repurposing proposal identifies nicorandil-mediated modulation of ABCC9 pathways as a potential treatment for hippocampal sclerosis of aging, an Alzheimer’s disease mimic, but the supplied finding reports no trial design, safety results, or clinical outcomes confirming benefit. [mechanism-plausible] (novelty: 3)
Open questions
Related
Contributing findings
Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging
10-nov-2026
novelty 3
per-area 3
strengthens